CD19 and acute lymphoblastic leukemia: We have learned that CD19-specific CAR T cells are effective at achieving early remissions in relapsed/refractory pediatric and young adult B-ALL, but the rate of lasting relapse-free curative outcomes lags behind with longer follow up.